Does the media prefer ORKA or ASND?

In the previous week, Ascendis Pharma A/S had 8 more articles in the media than Oruka Therapeutics. MarketBeat recorded 13 mentions for Ascendis Pharma A/S and 5 mentions for Oruka Therapeutics. Ascendis Pharma A/S's average media sentiment score of 1.10 beat Oruka Therapeutics' score of 0.19 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ascendis Pharma A/S 7 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ORKA or BBIO?

In the previous week, BridgeBio Pharma had 8 more articles in the media than Oruka Therapeutics. MarketBeat recorded 13 mentions for BridgeBio Pharma and 5 mentions for Oruka Therapeutics. BridgeBio Pharma's average media sentiment score of 1.19 beat Oruka Therapeutics' score of 0.19 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ORKA or ELAN?

In the previous week, Elanco Animal Health had 3 more articles in the media than Oruka Therapeutics. MarketBeat recorded 8 mentions for Elanco Animal Health and 5 mentions for Oruka Therapeutics. Elanco Animal Health's average media sentiment score of 1.19 beat Oruka Therapeutics' score of 0.19 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Elanco Animal Health 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AXSM or ORKA?

In the previous week, Axsome Therapeutics had 17 more articles in the media than Oruka Therapeutics. MarketBeat recorded 22 mentions for Axsome Therapeutics and 5 mentions for Oruka Therapeutics. Axsome Therapeutics' average media sentiment score of 0.67 beat Oruka Therapeutics' score of 0.19 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 12 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, SMMT or ORKA?

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Summit Therapeutics N/A N/A -$1.08B -$1.60 N/A Oruka Therapeutics N/A N/A -$105.43M -$1.94 N/A

Is SMMT or ORKA more profitable?

Oruka Therapeutics' return on equity of -26.16% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -291.24% -243.07% Oruka Therapeutics N/A -26.16% -25.00%

Does the media favor SMMT or ORKA?

In the previous week, Summit Therapeutics had 8 more articles in the media than Oruka Therapeutics. MarketBeat recorded 13 mentions for Summit Therapeutics and 5 mentions for Oruka Therapeutics. Summit Therapeutics' average media sentiment score of 0.84 beat Oruka Therapeutics' score of 0.19 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Oruka Therapeutics (ORKA) Competitors

$69.89 +1.42 (+2.07%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$69.56 -0.33 (-0.47%)

As of 06/12/2026 07:49 PM Eastern

Compare

ORKA vs. ASND, BBIO, ELAN, AXSM, and SMMT

Should you buy Oruka Therapeutics stock or one of its competitors? MarketBeat compares Oruka Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oruka Therapeutics include Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical products" industry.

How does Oruka Therapeutics compare to Ascendis Pharma A/S?

Oruka Therapeutics (NASDAQ:ORKA) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

In the previous week, Ascendis Pharma A/S had 8 more articles in the media than Oruka Therapeutics. MarketBeat recorded 13 mentions for Ascendis Pharma A/S and 5 mentions for Oruka Therapeutics. Ascendis Pharma A/S's average media sentiment score of 1.10 beat Oruka Therapeutics' score of 0.19 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a net margin of 57.87% compared to Oruka Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-26.16%	-25.00%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Oruka Therapeutics presently has a consensus target price of $131.30, suggesting a potential upside of 87.87%. Ascendis Pharma A/S has a consensus target price of $295.39, suggesting a potential upside of 35.46%. Given Oruka Therapeutics' higher possible upside, equities analysts clearly believe Oruka Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

56.4% of Oruka Therapeutics shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Oruka Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A
Ascendis Pharma A/S	$814.57M	16.70	-$258M	$8.67	25.15

Oruka Therapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

Summary

Ascendis Pharma A/S beats Oruka Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Oruka Therapeutics compare to BridgeBio Pharma?

Oruka Therapeutics (NASDAQ:ORKA) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

Oruka Therapeutics currently has a consensus price target of $131.30, suggesting a potential upside of 87.87%. BridgeBio Pharma has a consensus price target of $89.59, suggesting a potential upside of 34.12%. Given Oruka Therapeutics' higher probable upside, equities research analysts clearly believe Oruka Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.85

In the previous week, BridgeBio Pharma had 8 more articles in the media than Oruka Therapeutics. MarketBeat recorded 13 mentions for BridgeBio Pharma and 5 mentions for Oruka Therapeutics. BridgeBio Pharma's average media sentiment score of 1.19 beat Oruka Therapeutics' score of 0.19 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Pharma	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Oruka Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-26.16%	-25.00%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Oruka Therapeutics has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

Oruka Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. Oruka Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A
BridgeBio Pharma	$502.08M	26.06	-$724.93M	-$3.74	N/A

Summary

BridgeBio Pharma beats Oruka Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Oruka Therapeutics compare to Elanco Animal Health?

Oruka Therapeutics (NASDAQ:ORKA) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

Oruka Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-26.16%	-25.00%
Elanco Animal Health	-4.95%	7.42%	3.66%

Oruka Therapeutics has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market.

Oruka Therapeutics presently has a consensus price target of $131.30, indicating a potential upside of 87.87%. Elanco Animal Health has a consensus price target of $28.20, indicating a potential upside of 16.56%. Given Oruka Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Oruka Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Oruka Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A
Elanco Animal Health	$4.72B	2.56	-$232M	-$0.50	N/A

In the previous week, Elanco Animal Health had 3 more articles in the media than Oruka Therapeutics. MarketBeat recorded 8 mentions for Elanco Animal Health and 5 mentions for Oruka Therapeutics. Elanco Animal Health's average media sentiment score of 1.19 beat Oruka Therapeutics' score of 0.19 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elanco Animal Health	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 23.5% of Oruka Therapeutics shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Elanco Animal Health beats Oruka Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Oruka Therapeutics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

Oruka Therapeutics has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	20.57	-$183.17M	-$3.73	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A

Axsome Therapeutics presently has a consensus target price of $256.79, indicating a potential upside of 0.63%. Oruka Therapeutics has a consensus target price of $131.30, indicating a potential upside of 87.87%. Given Oruka Therapeutics' higher possible upside, analysts clearly believe Oruka Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

In the previous week, Axsome Therapeutics had 17 more articles in the media than Oruka Therapeutics. MarketBeat recorded 22 mentions for Axsome Therapeutics and 5 mentions for Oruka Therapeutics. Axsome Therapeutics' average media sentiment score of 0.67 beat Oruka Therapeutics' score of 0.19 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	12 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Axsome Therapeutics has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market.

Oruka Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Oruka Therapeutics' return on equity of -26.16% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Oruka Therapeutics	N/A	-26.16%	-25.00%

Summary

Axsome Therapeutics and Oruka Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Oruka Therapeutics compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

In the previous week, Summit Therapeutics had 8 more articles in the media than Oruka Therapeutics. MarketBeat recorded 13 mentions for Summit Therapeutics and 5 mentions for Oruka Therapeutics. Summit Therapeutics' average media sentiment score of 0.84 beat Oruka Therapeutics' score of 0.19 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by company insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summit Therapeutics currently has a consensus price target of $27.23, indicating a potential upside of 94.33%. Oruka Therapeutics has a consensus price target of $131.30, indicating a potential upside of 87.87%. Given Summit Therapeutics' higher possible upside, research analysts clearly believe Summit Therapeutics is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.47
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Oruka Therapeutics' return on equity of -26.16% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Oruka Therapeutics	N/A	-26.16%	-25.00%

Summit Therapeutics has a beta of -1.32, suggesting that its share price is 232% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market.

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A

Summary

Summit Therapeutics and Oruka Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Oruka Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORKA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORKA vs. The Competition

Export

Metric	Oruka Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.22B	$3.01B	$6.74B	$12.07B
Dividend Yield	N/A	1.76%	2.67%	5.67%
P/E Ratio	-36.03	18.84	24.21	24.42
Price / Sales	N/A	309.12	512.04	109.94
Price / Cash	N/A	55.88	27.48	37.92
Price / Book	7.21	3.98	10.66	6.83
Net Income	-$105.43M	$75.79M	$3.57B	$337.67M
7 Day Performance	16.21%	1.19%	0.84%	2.68%
1 Month Performance	9.37%	-3.70%	-0.34%	1.56%
1 Year Performance	456.45%	23.44%	25.40%	30.59%

Oruka Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORKA Oruka Therapeutics	2.7322 of 5 stars	$69.89 +2.1%	$131.30 +87.9%	+456.4%	$4.22B	N/A	N/A	N/A	News Coverage Analyst Downgrade Insider Trade
ASND Ascendis Pharma A/S	4.5437 of 5 stars	$210.45 -3.8%	$295.39 +40.4%	+27.7%	$13.65B	$814.57M	24.27	1,189	News Coverage Positive News Analyst Forecast
BBIO BridgeBio Pharma	3.6444 of 5 stars	$67.61 +0.4%	$89.59 +32.5%	+67.9%	$13.19B	$502.08M	N/A	400	Positive News
ELAN Elanco Animal Health	3.5563 of 5 stars	$23.61 -4.4%	$28.20 +19.4%	+75.1%	$12.34B	$4.72B	N/A	9,400	Positive News
AXSM Axsome Therapeutics	1.668 of 5 stars	$232.32 +0.4%	$251.26 +8.2%	+145.1%	$11.91B	$638.50M	N/A	380	News Coverage Analyst Upgrade Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORKA) was last updated on 6/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oruka Therapeutics (ORKA) Competitors

ORKA vs. ASND, BBIO, ELAN, AXSM, and SMMT

How does Oruka Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Oruka Therapeutics compare to BridgeBio Pharma?

Summary

How does Oruka Therapeutics compare to Elanco Animal Health?

Summary

How does Oruka Therapeutics compare to Axsome Therapeutics?

Summary

How does Oruka Therapeutics compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORKA vs. The Competition

Oruka Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oruka Therapeutics (ORKA) Competitors

ORKA vs. ASND, BBIO, ELAN, AXSM, and SMMT

How does Oruka Therapeutics compare to Ascendis Pharma A/S?

Does the media prefer ORKA or ASND?

Is ORKA or ASND more profitable?

Do analysts recommend ORKA or ASND?

Do institutionals and insiders hold more shares of ORKA or ASND?

Which has higher valuation and earnings, ORKA or ASND?

Which has more volatility and risk, ORKA or ASND?

Summary

How does Oruka Therapeutics compare to BridgeBio Pharma?

Do analysts recommend ORKA or BBIO?

Does the media prefer ORKA or BBIO?

Do insiders and institutionals hold more shares of ORKA or BBIO?

Is ORKA or BBIO more profitable?

Which has more volatility & risk, ORKA or BBIO?

Which has preferable earnings & valuation, ORKA or BBIO?

Summary

How does Oruka Therapeutics compare to Elanco Animal Health?

Is ORKA or ELAN more profitable?

Which has more volatility & risk, ORKA or ELAN?

Do analysts recommend ORKA or ELAN?

Which has preferable valuation & earnings, ORKA or ELAN?

Does the media prefer ORKA or ELAN?

Do institutionals and insiders believe in ORKA or ELAN?

Summary

How does Oruka Therapeutics compare to Axsome Therapeutics?

Which has better earnings & valuation, AXSM or ORKA?

Do analysts prefer AXSM or ORKA?

Does the media favor AXSM or ORKA?

Do institutionals & insiders have more ownership in AXSM or ORKA?

Which has more risk & volatility, AXSM or ORKA?

Is AXSM or ORKA more profitable?

Summary

How does Oruka Therapeutics compare to Summit Therapeutics?

Does the media favor SMMT or ORKA?

Do insiders & institutionals have more ownership in SMMT or ORKA?

Do analysts prefer SMMT or ORKA?

Is SMMT or ORKA more profitable?

Which has more risk and volatility, SMMT or ORKA?

Which has higher valuation & earnings, SMMT or ORKA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORKA vs. The Competition

Oruka Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools